Acromegaly - Before and After Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03431727 |
Recruitment Status : Unknown
Verified December 2020 by University of Aarhus.
Recruitment status was: Recruiting
First Posted : February 13, 2018
Last Update Posted : December 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Acromegaly Growth Hormone Treatment Sleep Apnea Cardiovascular Diseases Bone Diseases |
Study Type : | Observational |
Estimated Enrollment : | 20 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Sleep Apnea, Circulation and Metabolism in Acromegaly - Before and After Treatment |
Actual Study Start Date : | October 1, 2017 |
Estimated Primary Completion Date : | December 1, 2022 |
Estimated Study Completion Date : | December 1, 2022 |
- Sleep apnea [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]ApneaLinkAir: respiratory effort, puls, oxygen saturation, nasal flow and snoring
- Circulation [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]Sphygmocor: central arterial pressure and pulse wave velocity
- Bone metabolism [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]HRpQCT scan
- Heartfunction [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]Echocardiography
- Substrate metabolism; signaling proteins [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]Western blotting
- Substrate metabolism; gene targets [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]qPCR
- Energy expenditure [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]Indirect calorimetry
- Body composition [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]DXA scan
- Physical activity [ Time Frame: At baseline (time of diagnosis) and at an average of 1 years treatment ]Sensoriband
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Recently diagnosed with acromegaly
- Age above 18
- Written consent
Exclusion Criteria:
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03431727
Contact: Mai C Arlien-Søborg, MD | +45 23837420 | mas@clin.au.dk | |
Contact: Jens Otto L Jørgensen, Professor | +45 24800664 | joj@clin.au.dk |
Denmark | |
Aarhus University Hospital, Department of internal medicine and endocrinologi | Recruiting |
Aarhus, Denmark, 8000 | |
Contact: Mai C Arlien-Søborg, MD +45 23837420 mas@clin.au.dk | |
Principal Investigator: Jens Otto L Jørgensen, Professor | |
Sub-Investigator: Mai C Arlien-Søborg, MD |
Principal Investigator: | Jens Otto L Jørgensen, Porfessor | Aarhus University Hospital, Department of internal medicine and endocrinology |
Responsible Party: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT03431727 |
Other Study ID Numbers: |
1-10-72-126-16 |
First Posted: | February 13, 2018 Key Record Dates |
Last Update Posted: | December 7, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Acromegaly Bone Diseases Sleep Apnea Syndromes Cardiovascular Diseases Apnea Respiration Disorders Respiratory Tract Diseases Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders |
Nervous System Diseases Bone Diseases, Endocrine Musculoskeletal Diseases Hyperpituitarism Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Endocrine System Diseases |